VJHemOnc is committed to improving our service to you

MDS 2020 | Transfusion-dependant, low-risk MDS: what are the options?

VJHemOnc is committed to improving our service to you

Valeria Santini

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the therapy options for transfusion-dependent, low-risk myelodysplastic syndromes (MDS) patients. Specifically, the stimulation of erythropoiesis with the TGF-β targetting galunisertib and the ligand-trapping luspatercept and sotatercept is outlined. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter